Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider Aranthan Jones II sold 7,313 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $10.62, for a total transaction of $77,664.06. Following the completion of the transaction, the insider now owns 82,687 shares in the company, valued at $878,135.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
VNDA opened at $10.08 on Friday. The stock has a market capitalization of $549.86 million, a price-to-earnings ratio of 4.71 and a beta of 0.54. The company has a fifty day moving average of $11.23 and a 200 day moving average of $11.64. Vanda Pharmaceuticals Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $17.85.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The company had revenue of $58.00 million during the quarter, compared to analysts’ expectations of $57.53 million. Vanda Pharmaceuticals had a net margin of 49.12% and a return on equity of 30.60%. On average, analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.31 earnings per share for the current year.
Several research analysts have weighed in on VNDA shares. ValuEngine downgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, May 1st. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 11th. BidaskClub cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Citigroup cut shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $14.00 price objective for the company. in a research note on Tuesday, June 9th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.40.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Featured Article: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.